Why Neurologists Start with Beta Blockers and Antidepressants: A Migraine Medication Deep Dive

0:00 – Speaker 1: Have you ever like taken a medication

0:01 – Speaker 1: for one thing only to find it magically

0:04 – Speaker 1: cured something else entirely?

0:05 – Speaker 2: Oh yeah. Like it just completely fixes a

0:07 – Speaker 2: totally unrelated problem.

0:09 – Speaker 1: Right. So you take um an antihistamine

0:11 – Speaker 1: for your seasonal allergies and suddenly

0:13 – Speaker 1: that weird patch of dry skin you’ve had

0:15 – Speaker 1: for months just vanishes.

0:17 – Speaker 2: Right. Right.

0:17 – Speaker 1: It sounds like a total fluke, but um

0:20 – Speaker 1: that kind of happy accident is actually

0:23 – Speaker 1: the absolute foundation of modern

0:25 – Speaker 1: headache medicine.

0:25 – Speaker 2: It really is. It’s wild. So today we are

0:28 – Speaker 2: taking a deep dive into this incredibly

0:30 – Speaker 2: comprehensive clinical resource document

0:33 – Speaker 2: from the migraine surgery specialty

0:35 – Speaker 2: center and our mission is to explore the

0:37 – Speaker 2: history the biological mechanisms the

0:40 – Speaker 2: risks and you know the real world

0:42 – Speaker 2: limitations of the two biggest

0:44 – Speaker 2: heavyweights in migraine prevention

0:46 – Speaker 2: which are beta blockers and

0:48 – Speaker 2: anti-depressants.

0:49 – Speaker 1: Exactly. And crucially we are going to

0:51 – Speaker 1: look at what happens when those

0:52 – Speaker 1: foundational tools just completely fail

0:55 – Speaker 1: you.

0:55 – Speaker 2: Yeah. And if we connect this to the

0:57 – Speaker 2: bigger picture, the history of migraine

0:59 – Speaker 2: treatment reveals this really

1:00 – Speaker 2: fascinating truth about medicine in

1:02 – Speaker 2: general. Well, for decades, the primary

1:06 – Speaker 2: pharmarmacological treatments we used

1:07 – Speaker 2: for chronic migraines, they weren’t

1:09 – Speaker 2: actually developed for headaches at all.

1:11 – Speaker 1: Wait, really?

1:12 – Speaker 2: Yeah. I mean, clinical observation often

1:14 – Speaker 2: outpaces our biological understanding by

1:16 – Speaker 2: years, sometimes even decades. We

1:19 – Speaker 2: frequently see that a treatment works in

1:21 – Speaker 2: the real world long before we have the

1:23 – Speaker 2: uh the scientific capability to actually

1:27 – Speaker 2: understand why it works in the body.

1:28 – Speaker 1: Okay, let’s unpack this history because

1:30 – Speaker 1: the way these drugs were discovered is

1:32 – Speaker 1: just wild to me. We are talking about

1:35 – Speaker 1: medications designed for the heart and

1:37 – Speaker 1: the mood somehow like fixing the head,

1:39 – Speaker 1: right?

1:40 – Speaker 1: Take us back to how this actually

1:41 – Speaker 1: started. So the story really begins in

1:44 – Speaker 1: the early 1960s with a scientist named

1:46 – Speaker 1: Sir James Black and he actually

1:48 – Speaker 1: eventually won a Nobel Prize for this

1:50 – Speaker 1: work.

1:51 – Speaker 2: Oh wow. Okay.

1:51 – Speaker 1: Yeah. He synthesized a drug called

1:54 – Speaker 1: propranolol which is a beta blocker. Now

1:57 – Speaker 1: black developed propranol specifically

1:59 – Speaker 1: to treat anggina which is you know

2:01 – Speaker 1: severe chest pain and cardiac

2:03 – Speaker 1: arhythmias.

2:04 – Speaker 2: So he was strictly looking at the heart

2:05 – Speaker 2: entirely. He was focused entirely on

2:08 – Speaker 2: cardiovascular medicine. He was just

2:09 – Speaker 2: trying to find a way to reduce the

2:12 – Speaker 2: workload on the heart.

2:13 – Speaker 1: Okay, so he’s looking exclusively at the

2:15 – Speaker 1: cardiovascular system. But then a few

2:17 – Speaker 1: years later around 1966, a researcher

2:20 – Speaker 1: named Rabkin starts treating his cardiac

2:23 – Speaker 1: patients with this new drug propranol.

2:26 – Speaker 2: Yes.

2:27 – Speaker 1: And from the source material, it sounds

2:28 – Speaker 1: like he just completely stumbles into

2:30 – Speaker 1: the secondary effect. His patients are

2:32 – Speaker 1: coming in for their heart checkups, and

2:34 – Speaker 1: they casually mention that their

2:35 – Speaker 1: debilitating migraines have just

2:37 – Speaker 1: vanished.

2:37 – Speaker 2: Yeah, that casual observation

2:39 – Speaker 2: basically changed the entire trajectory

2:41 – Speaker 2: of headache medicine. You have to

2:43 – Speaker 2: imagine the clinical setting in the

2:44 – Speaker 2: 1960s, right? A cardiologist is not

2:47 – Speaker 2: screening for migraines,

2:48 – Speaker 1: right? They don’t care about your head.

2:49 – Speaker 2: Exactly. These patients were just

2:51 – Speaker 2: volunteering the information because the

2:53 – Speaker 2: relief was so profound. They were

2:56 – Speaker 2: describing the disappearance of their

2:57 – Speaker 2: migraines simply as like a side benefit

3:00 – Speaker 2: of their heart disease treatment.

3:01 – Speaker 1: That’s incredible.

3:02 – Speaker 2: It is. And the medical community

3:04 – Speaker 2: definitely took notice. By the 1970s,

3:07 – Speaker 2: rigorous controlled trials confirmed

3:09 – Speaker 2: Rabkins anecdotal observation. And

3:11 – Speaker 2: ultimately in 1979, proprenal became the

3:15 – Speaker 2: very first beta blocker to receive

3:17 – Speaker 2: formal FDA approval for migraine

3:20 – Speaker 2: prophylaxis or prevention.

3:22 – Speaker 1: What strikes me is that lightning

3:23 – Speaker 1: basically struck twice in the exact same

3:26 – Speaker 1: decade because a very similar accidental

3:28 – Speaker 1: discovery happened with

3:29 – Speaker 1: anti-depressants.

3:29 – Speaker 2: Right.

3:30 – Speaker 2: It did. Just two years before Rapkins

3:33 – Speaker 2: observation with the beta blocker. So in

3:35 – Speaker 2: 1964, two researchers named Lance and

3:38 – Speaker 2: Curran published this landmark paper on

3:40 – Speaker 2: a drug called amatipptaline.

3:42 – Speaker 1: Okay.

3:42 – Speaker 2: Now, amatipptalign had just hit the

3:44 – Speaker 2: market in 1961 as a tricyclic

3:46 – Speaker 2: anti-depressant primarily for major

3:48 – Speaker 2: depressive disorder. But Lance and

3:50 – Speaker 2: Curran noticed it produced these

3:51 – Speaker 2: striking reductions in migraine

3:53 – Speaker 2: frequency in their patients.

3:55 – Speaker 2: And it even seemed to alleviate chronic

3:57 – Speaker 2: tension type headaches.

3:58 – Speaker 1: Okay, but I’m looking at these two

3:59 – Speaker 1: groups of patients, the ones taking it

4:01 – Speaker 1: for depression and the ones taking it

4:02 – Speaker 1: for migraines. And the math just isn’t

4:04 – Speaker 1: adding up for me.

4:05 – Speaker 2: How so?

4:06 – Speaker 1: Well, if a drug is designed to treat

4:07 – Speaker 1: major clinical depression,

4:09 – Speaker 1: are the migraine patients taking those

4:12 – Speaker 1: same massive doses? Like, do you have to

4:14 – Speaker 1: treat a migraine with a full psychiatric

4:17 – Speaker 1: level dose of an anti-depressant?

4:18 – Speaker 2: Oh, no, not at all. That dosage

4:21 – Speaker 2: discrepancy is actually the most

4:22 – Speaker 2: important part of the discovery.

4:23 – Speaker 1: Oh, really?

4:24 – Speaker 2: Yeah. The migraine patients were

4:26 – Speaker 2: responding to much, much lower doses

4:28 – Speaker 2: than the psychiatric patients. And

4:30 – Speaker 2: furthermore, the headache relief was

4:32 – Speaker 2: happening way faster.

4:34 – Speaker 1: Interesting.

4:34 – Speaker 2: Because anti-depressants typically take

4:36 – Speaker 2: weeks to build up in the system to alter

4:38 – Speaker 2: mood, right? But the headache relief was

4:41 – Speaker 2: occurring rapidly.

4:42 – Speaker 1: Oh, I see. It’s almost like um

4:44 – Speaker 1: discovering that the same chemical that

4:46 – Speaker 1: cleaned your oven also fertilizes your

4:48 – Speaker 1: garden, but only if you dilute it to a

4:50 – Speaker 1: tiny fraction of the strength.

4:51 – Speaker 2: That’s a great way to put it.

4:52 – Speaker 1: It proves it’s doing two completely

4:54 – Speaker 1: different jobs.

4:55 – Speaker 2: Exactly. That dualpurpose analogy gets

4:57 – Speaker 2: us right to the biological truth. That

4:59 – Speaker 2: specific discrepancy in dosing and

5:01 – Speaker 2: timing proved that the analesic or pain

5:03 – Speaker 2: relieving mechanism in the brain was

5:06 – Speaker 2: entirely separate from the mood

5:07 – Speaker 2: elevating mechanism. It meant a patient

5:10 – Speaker 2: didn’t have to be clinically depressed

5:12 – Speaker 2: to experience the headache benefit. That

5:14 – Speaker 2: realization cemented these lowdosese

5:17 – Speaker 2: anti-depressants as legitimate

5:19 – Speaker 2: independent headache treatments totally

5:22 – Speaker 2: separate from their psychiatric

5:23 – Speaker 2: applications.

5:24 – Speaker 1: Okay. So if we know that these happy

5:26 – Speaker 1: accidents gave us these two categories

5:28 – Speaker 1: of drugs, we have to look at the

5:30 – Speaker 1: underlying mechanics. Let’s start with

5:32 – Speaker 1: the beta blockers.

5:33 – Speaker 2: Sure.

5:34 – Speaker 1: Why on earth does a medication designed

5:36 – Speaker 1: to slow down a racing heart also calm a

5:40 – Speaker 1: severe migraine?

5:41 – Speaker 2: Well, the neurobiology of a migraine is

5:44 – Speaker 2: incredibly complex and candidly we still

5:46 – Speaker 2: don’t have a perfect unified theory

5:48 – Speaker 2: really still

5:49 – Speaker 2: still. But we do have several strongly

5:52 – Speaker 2: proposed mechanisms for beta blockers.

5:54 – Speaker 2: First, they reduce the overall tone of

5:56 – Speaker 2: the sympathetic nervous system.

5:58 – Speaker 1: Let’s break that down for the listener.

5:59 – Speaker 1: The sympathetic nervous system is that

6:01 – Speaker 1: like our basic fight orflight response.

6:03 – Speaker 2: Seriously, it’s the system that pumps

6:04 – Speaker 2: adrenaline, dilates your pupils, and

6:06 – Speaker 2: constricts your blood vessels when you

6:08 – Speaker 2: perceive a threat. So, by blocking the

6:10 – Speaker 2: beta receptors that respond to

6:12 – Speaker 2: adrenaline, the drug lowers that fight

6:14 – Speaker 2: orflight tone. This decreases the

6:17 – Speaker 2: reactivity of the smooth muscle lining

6:19 – Speaker 2: your blood vessels, which prevents the

6:20 – Speaker 2: painful vascular throbbing associated

6:23 – Speaker 2: with migraines.

6:23 – Speaker 1: That makes sense.

6:24 – Speaker 1: But the other major theory is even more

6:26 – Speaker 1: fascinating. It’s believed beta blockers

6:28 – Speaker 1: suppress something called cortical

6:30 – Speaker 1: spreading depression or CSD.

6:32 – Speaker 2: Cortical spreading depression.

6:34 – Speaker 1: Um, I want to make sure I’m visualizing

6:36 – Speaker 1: this correctly. The source describes it

6:38 – Speaker 1: as a wave of depolarization.

6:41 – Speaker 2: Right. So, is this essentially like an

6:43 – Speaker 2: electrical blackout rolling across the

6:45 – Speaker 2: surface of the brain? Like a slow wave

6:48 – Speaker 2: that just shuts down normal neuronal

6:50 – Speaker 2: activity which then triggers that

6:52 – Speaker 2: classic visual aura people get before

6:54 – Speaker 2: the pain hits.

6:55 – Speaker 1: The rolling blackout is a very accurate

6:57 – Speaker 1: way to visualize it. Okay, good.

6:59 – Speaker 1: Imagine a wave of dominoes slowly

7:01 – Speaker 1: falling across the surface of the brain,

7:02 – Speaker 1: the cortex. As those neurons depolarize

7:05 – Speaker 1: and essentially shortcircuit, it alters

7:08 – Speaker 1: blood flow and triggers massive pain

7:10 – Speaker 1: signals down into the trigeminal nerve.

7:12 – Speaker 2: And that’s the main nerve for the head.

7:13 – Speaker 1: Yeah. It’s the main sensory nerve of the

7:15 – Speaker 1: head and face. So, beta blockers seem to

7:18 – Speaker 1: stabilize the electrical excitability of

7:20 – Speaker 1: the brain. They make those dominoes

7:22 – Speaker 1: heavier, so to speak, making it much

7:24 – Speaker 1: harder for that rolling blackout to ever

7:26 – Speaker 1: get started.

7:26 – Speaker 2: So, if you’re listening to this and

7:28 – Speaker 2: experiencing this, who is actually the

7:30 – Speaker 2: ideal candidate for a beta blocker?

7:32 – Speaker 1: According to the clinical guidelines,

7:34 – Speaker 1: they are primarily indicated for

7:35 – Speaker 1: patients with episodic migraines, which

7:38 – Speaker 1: usually means experiencing four or more

7:40 – Speaker 1: distinct migraine days a month,

7:42 – Speaker 1: especially if those attacks are

7:43 – Speaker 1: disabling and interfering with daily

7:45 – Speaker 1: life.

7:45 – Speaker 2: Got it.

7:46 – Speaker 1: And they’re particularly favored for

7:48 – Speaker 1: what we might call a dualbenefit

7:50 – Speaker 1: approach,

7:50 – Speaker 2: like killing two birds with one stone.

7:52 – Speaker 1: Exactly. If a patient suffers from

7:54 – Speaker 1: chronic migraines but also happens to

7:56 – Speaker 1: have hypertension or essential tremors

7:59 – Speaker 1: or severe physical anxiety symptoms like

8:01 – Speaker 1: a pounding heart.

8:02 – Speaker 2: Oh wow.

8:03 – Speaker 1: Yeah. A beta blocker like propranol or

8:05 – Speaker 1: metiprolol can treat all of those

8:07 – Speaker 1: conditions simultaneously with one pill.

8:10 – Speaker 2: But we have to talk about the real world

8:12 – Speaker 2: experience of taking these because the

8:14 – Speaker 2: side effects are a major hurdle. The

8:17 – Speaker 2: text notes that profound fatigue is the

8:19 – Speaker 2: number one reason people quit taking

8:21 – Speaker 2: beta blockers.

8:21 – Speaker 1: It is.

8:23 – Speaker 2: And that makes sense. I mean, if you are

8:25 – Speaker 2: chemically suppressing someone’s fight

8:26 – Speaker 2: or-flight adrenaline response, they are

8:29 – Speaker 2: going to feel lethargic.

8:30 – Speaker 1: Absolutely.

8:31 – Speaker 2: You also get cold hands and feet, brady

8:33 – Speaker 2: cardia, which is a resting heart rate

8:34 – Speaker 2: that drops too low, and for some people,

8:37 – Speaker 2: incredibly vivid, disturbing nightmares.

8:40 – Speaker 1: Yeah. The nightmares are a very specific

8:42 – Speaker 1: and troubling side effect for many

8:44 – Speaker 1: patients. This happens primarily with

8:46 – Speaker 1: what we call lipophilic beta blockers

8:48 – Speaker 1: like proprenol.

8:49 – Speaker 2: What does lipohilic mean in this

8:51 – Speaker 2: context? Lipophilic literally means

8:53 – Speaker 2: fatloving. These drugs dissolve easily

8:55 – Speaker 2: in fats.

8:56 – Speaker 1: Okay?

8:57 – Speaker 2: Because the human brain is composed

9:00 – Speaker 2: largely of fat and the protective

9:00 – Speaker 2: barrier surrounding the brain, the

9:01 – Speaker 2: bloodb brain barrier is highly

9:04 – Speaker 2: lipid-based lipophilic drugs crossed

9:07 – Speaker 2: right over into the central nervous

9:08 – Speaker 2: system,

9:09 – Speaker 1: which is what you want for a migraine.

9:10 – Speaker 2: Right.

9:10 – Speaker 1: Right. That’s fantastic for getting the

9:13 – Speaker 1: drug into the brain to stop the

9:15 – Speaker 1: migraine, but it also means the drug is

9:16 – Speaker 1: in there actively interfering with your

9:18 – Speaker 1: sleep architecture and your REM cycles.

9:20 – Speaker 2: Yikes.

9:21 – Speaker 1: So, if a patient is struggling with

9:23 – Speaker 1: those nightmares, a clinician will often

9:25 – Speaker 1: switch them to a hydrophilic or water

9:28 – Speaker 1: loving beta blocker, which doesn’t cross

9:30 – Speaker 1: the bloodb brain barrier nearly as

9:32 – Speaker 1: easily.

9:33 – Speaker 2: Wait, I want to push back on something

9:34 – Speaker 2: here.

9:34 – Speaker 1: Okay,

9:35 – Speaker 2: if these drugs are essentially just

9:36 – Speaker 2: calming the brain’s excitability and

9:39 – Speaker 2: gently lowering blood pressure,

9:40 – Speaker 1: right?

9:41 – Speaker 2: Why is this so strictly regulated? Like

9:43 – Speaker 2: if it calms your nervous system down,

9:45 – Speaker 2: couldn’t a lowd dose beta blocker

9:47 – Speaker 2: eventually just be something we get over

9:49 – Speaker 2: the counter like ibuprofen for a bad

9:51 – Speaker 2: migraine?

9:52 – Speaker 1: That sounds logical until you look at

9:54 – Speaker 1: how the sympathetic nervous system

9:55 – Speaker 1: interacts with other systemic diseases.

9:57 – Speaker 1: It isn’t just about calming the brain.

9:59 – Speaker 2: What do you mean?

10:00 – Speaker 1: For example, consider an insulin

10:01 – Speaker 1: dependent diabetic. When a diabetic

10:04 – Speaker 1: patients blood sugar crashes dangerously

10:06 – Speaker 1: low a state called hypoglycemia,

10:08 – Speaker 1: their body releases a surge of

10:09 – Speaker 1: adrenaline to warn them. Their heart

10:11 – Speaker 1: starts racing. Their hands shake. It’s

10:14 – Speaker 1: an alarm bell.

10:15 – Speaker 2: And the beta blocker unplugged the alarm

10:16 – Speaker 2: bell.

10:17 – Speaker 1: Exactly. The beta blocker suppresses

10:19 – Speaker 1: that adrenaline response. The heart

10:21 – Speaker 1: doesn’t race. The patient literally

10:23 – Speaker 1: loses their body’s early warning system

10:26 – Speaker 1: for a lethal blood sugar crash.

10:28 – Speaker 2: Oh wow, that’s terrifying.

10:30 – Speaker 1: It is. That phenomenon is called

10:32 – Speaker 1: hypoglycemic unawareness, and it’s

10:34 – Speaker 1: incredibly dangerous. Furthermore, in

10:36 – Speaker 1: patients with asthma, beta blockers can

10:39 – Speaker 1: trigger severe bronco spasms, basically

10:41 – Speaker 1: closing the airways.

10:42 – Speaker 2: Right?

10:43 – Speaker 1: This is why these require intense

10:45 – Speaker 1: medical oversight. You cannot apply a

10:47 – Speaker 1: systemic nervous system dampener without

10:49 – Speaker 1: looking at the whole patient,

10:51 – Speaker 2: which perfectly explains why doctors

10:52 – Speaker 2: needed another option. Because beta

10:55 – Speaker 2: blockers act like a speed limit on the

10:56 – Speaker 2: cardiovascular system, doctors realized

10:59 – Speaker 2: their hands were tied if a migraine

11:01 – Speaker 2: patient already had asthma or low blood

11:03 – Speaker 2: pressure or diabetes.

11:03 – Speaker 1: Exactly.

11:05 – Speaker 1: They couldn’t use the heart medication

11:07 – Speaker 1: back door. They needed a different

11:09 – Speaker 1: systemic approach that bypass the heart

11:11 – Speaker 1: entirely. And that brings us directly to

11:13 – Speaker 1: the anti-depressants.

11:14 – Speaker 2: That’s the exact clinical pivot. When

11:17 – Speaker 2: the cardiovascular route is blocked, we

11:19 – Speaker 2: look to the neurotransmitter route.

11:21 – Speaker 2: Let’s start with the older class that

11:23 – Speaker 2: Lance and Curran discovered, the

11:25 – Speaker 2: tricyclic anti-depressants or TCAs like

11:28 – Speaker 2: emitine.

11:29 – Speaker 1: Okay. To understand how they work, we

11:31 – Speaker 1: have to look at the microscopic gaps

11:33 – Speaker 1: between your neurons called synaptic

11:35 – Speaker 1: clfts.

11:35 – Speaker 2: Okay, so the synaptic clft is the empty

11:37 – Speaker 2: space where one brain cell throws a

11:40 – Speaker 2: chemical messenger across to the next

11:42 – Speaker 2: brain cell to pass along a signal.

11:44 – Speaker 1: That’s a great visualization. Now,

11:45 – Speaker 1: normally after a messenger chemical like

11:47 – Speaker 1: serotonin is thrown across that gap, the

11:49 – Speaker 1: first brain cell vacuums it back up to

11:51 – Speaker 1: recycle it.

11:51 – Speaker 2: Okay,

11:52 – Speaker 1: that vacuuming process is called

11:54 – Speaker 1: re-uptake. TCAs block that vacuum. They

11:56 – Speaker 1: are re-uptake inhibitors. So the

11:58 – Speaker 1: chemical just stays there.

12:00 – Speaker 2: Exactly. By plugging the vacuum, they

12:02 – Speaker 2: force vital neurotransmitters,

12:04 – Speaker 2: specifically serotonin and

12:05 – Speaker 2: norepinephrine, to pull and remain

12:07 – Speaker 2: active in that gap for much longer.

12:09 – Speaker 1: And what does that do?

12:10 – Speaker 2: Clinically, keeping more of those

12:11 – Speaker 2: chemicals active raises the pain

12:13 – Speaker 2: threshold in the brain stem. It

12:15 – Speaker 2: strengthens your body’s own internal

12:17 – Speaker 2: descending pain modulating pathways.

12:20 – Speaker 1: Okay, so you mentioned TCA’s boost

12:22 – Speaker 1: serotonin and norepinephrine, but what

12:24 – Speaker 1: about the elephant in the room? SSRIs,

12:26 – Speaker 1: right? Drugs like Prozac or Zoloft are

12:29 – Speaker 1: incredibly common. Selective serotonin

12:32 – Speaker 1: reuptake inhibitors.

12:33 – Speaker 1: If they also block that vacuum and leave

12:36 – Speaker 1: more serotonin in the gap, do they work

12:38 – Speaker 1: for migraines?

12:39 – Speaker 2: They actually don’t. And the clinical

12:42 – Speaker 2: failure of SSRI for migraines provided a

12:44 – Speaker 2: really crucial biological insight.

12:46 – Speaker 1: Oh, really?

12:47 – Speaker 2: Yeah. As the name suggests, SSRIs are

12:50 – Speaker 2: selective. They only boost serotonin.

12:53 – Speaker 2: SNRIs like benlaxine boost both

12:55 – Speaker 2: serotonin and norepinephrine.

12:57 – Speaker 1: Okay.

12:57 – Speaker 2: What the trial data conclusively showed

12:59 – Speaker 2: is that boosting serotonin alone is not

13:02 – Speaker 2: enough to reliably reduce headache

13:03 – Speaker 2: frequency. Norepinephrine is the

13:05 – Speaker 2: absolute key to turning down the brain’s

13:07 – Speaker 2: pain dial.

13:08 – Speaker 1: Interesting.

13:08 – Speaker 2: You must have that neuronurgic activity

13:10 – Speaker 2: to get the migraine prophylaxis benefit.

13:12 – Speaker 1: [snorts]

13:12 – Speaker 1: So it’s the norepinephrine doing the

13:14 – Speaker 1: heavy lifting for the pain.

13:14 – Speaker 2: Yep.

13:15 – Speaker 1: But as effective as those older TCAs

13:17 – Speaker 1: are, they come with a heavy toll on the

13:19 – Speaker 1: body.

13:20 – Speaker 2: They do. TCAs are notorious for their

13:22 – Speaker 2: anticolinergic side effects.

13:24 – Speaker 1: Let’s translate anticolinergic for the

13:26 – Speaker 1: listener because the source lists a lot

13:28 – Speaker 1: of really unpleasant symptoms under that

13:31 – Speaker 1: umbrella.

13:31 – Speaker 2: Right? So acetylcholine is a

13:33 – Speaker 2: neurotransmitter that basically tells

13:35 – Speaker 2: your body to rest and digest. It

13:37 – Speaker 2: stimulates saliva production, keeps your

13:38 – Speaker 2: bowels moving, and controls certain

13:41 – Speaker 2: muscle contractions.

13:42 – Speaker 1: Okay.

13:43 – Speaker 2: TCAs accidentally block acetylcholine.

13:46 – Speaker 2: So when you block the rest and digest

13:48 – Speaker 2: messenger, your salivary gland shut down

13:51 – Speaker 2: resulting in severe dry mouth.

13:53 – Speaker 2: Your digestive tract slows to a crawl

13:55 – Speaker 2: causing constipation and significant

13:57 – Speaker 2: weight gain. You also experience heavy

14:00 – Speaker 2: sedation.

14:00 – Speaker 1: And beyond the daily discomfort, the

14:02 – Speaker 1: text mentions a narrow therapeutic

14:04 – Speaker 1: index, meaning the gap between the dose

14:06 – Speaker 1: that helps you and the dose that could

14:08 – Speaker 1: harm you is dangerously small.

14:10 – Speaker 2: Right? That is the most critical risk

14:12 – Speaker 2: factor with TCAs. In an overdose

14:14 – Speaker 2: situation, because of that narrow

14:16 – Speaker 2: therapeutic index, TCAs can cause lethal

14:18 – Speaker 2: cardiac arhythmias.

14:20 – Speaker 1: Wow.

14:20 – Speaker 2: Clinicians have to be extremely careful

14:22 – Speaker 2: prescribing them, especially to older

14:24 – Speaker 2: patients or anyone with active suicidal

14:26 – Speaker 2: ideiation because they are highly toxic

14:28 – Speaker 2: in overdosing.

14:29 – Speaker 1: Which makes the shift to newer drugs

14:31 – Speaker 1: like SNRIs, make total sense.

14:34 – Speaker 2: Exactly. The source highlights that

14:36 – Speaker 2: SNRIs and other newer agents like

14:38 – Speaker 2: delloxitine offer a much cleaner side

14:41 – Speaker 2: effect profile. You bypass that heavy

14:43 – Speaker 2: antiolineric burdenless dry mouth, less

14:46 – Speaker 2: weight gain, less sedation.

14:47 – Speaker 1: Yeah, it’s a huge improvement.

14:49 – Speaker 2: Plus, deluxitine is actually FDA

14:51 – Speaker 2: approved for fibromyalgia.

14:53 – Speaker 1: So, if a patient has chronic migraines

14:55 – Speaker 1: and widespread muscularkeeletal pain,

14:58 – Speaker 1: they get another dual benefit scenario.

15:00 – Speaker 2: The evolution of these medications is

15:02 – Speaker 2: really about refining the target to

15:04 – Speaker 2: minimize collateral damage. And this

15:06 – Speaker 2: leads us to the daily reality of

15:07 – Speaker 2: headache medicine, which is essentially

15:09 – Speaker 2: a complex matchmaking game.

15:11 – Speaker 1: Oh, I see.

15:12 – Speaker 2: The clinician has to match the

15:13 – Speaker 2: pharmacological profile of the drug to

15:15 – Speaker 2: the unique coorbidities of the patient

15:17 – Speaker 2: sitting in front of them.

15:18 – Speaker 1: Let’s look at that clinical

15:19 – Speaker 1: decision-making matrix. You walk into

15:21 – Speaker 1: the clinic, you have migraines and high

15:23 – Speaker 1: blood pressure. The doctor gives you a

15:24 – Speaker 1: beta blocker,

15:25 – Speaker 2: right?

15:26 – Speaker 1: Migraines and terrible insomnia. They

15:28 – Speaker 1: might give you a low dose sedating TCA

15:31 – Speaker 1: to take at bedtime so it knocks you out,

15:33 – Speaker 1: prevents the headache, migraines, and

15:35 – Speaker 1: asthma. They avoid the beta blocker

15:38 – Speaker 1: entirely to prevent an asthma attack.

15:40 – Speaker 1: And they look at an SNRI. It’s a total

15:42 – Speaker 1: puzzle.

15:43 – Speaker 2: It is a highly individualized puzzle.

15:45 – Speaker 2: But even with perfect evidence-based

15:48 – Speaker 2: matchmaking, we have to talk about

15:50 – Speaker 2: managing patient expectations.

15:52 – Speaker 1: Okay.

15:52 – Speaker 2: The statistics in the source material

15:54 – Speaker 2: regarding efficacy are quite sobering.

15:57 – Speaker 2: In migraine prophylaxis research, the

15:59 – Speaker 2: gold standard benchmark for a successful

16:01 – Speaker 2: trial is called the 50% responder rate.

16:04 – Speaker 1: Eating one.

16:04 – Speaker 2: The primary goal of these massive drug

16:06 – Speaker 2: trials is merely to see if the

16:08 – Speaker 2: medication can reduce the number of

16:10 – Speaker 2: migraine days by half.

16:11 – Speaker 1: That feels like a really low bar for a

16:13 – Speaker 1: medical trial. Like how many people

16:14 – Speaker 1: actually hit that 50% mark?

16:16 – Speaker 2: Across the board. Looking at the data

16:18 – Speaker 2: for both beta blockers and

16:20 – Speaker 2: anti-depressants, only about 40 to 55%

16:23 – Speaker 2: of patients ever achieve that 50%

16:25 – Speaker 2: reduction in headache frequency.

16:27 – Speaker 1: Wow. So, if you are listening to this

16:29 – Speaker 1: right now and you’ve given up on a daily

16:31 – Speaker 1: migraine pill after 3 or 4 weeks because

16:33 – Speaker 1: it felt like it wasn’t doing anything,

16:35 – Speaker 1: you weren’t impatient. You were just

16:36 – Speaker 1: reacting to a really frustrating trial

16:39 – Speaker 1: and error process.

16:40 – Speaker 2: Basically, it’s a coin flip whether the

16:42 – Speaker 2: drug will cut your migraines in half.

16:44 – Speaker 2: And the source explicitly notes it takes

16:46 – Speaker 2: 8 to 12 weeks of continuous daily use

16:49 – Speaker 2: just to see if it even works. A quarter

16:52 – Speaker 2: of a year just waiting to see if your

16:54 – Speaker 2: pain is cut by 50%.

16:55 – Speaker 1: The psychological toll of that waiting

16:57 – Speaker 1: period is immense. There’s a reason the

17:00 – Speaker 1: clinical text specifically notes that

17:02 – Speaker 1: unrealistic expectations are a major

17:05 – Speaker 1: driver of early premature

17:07 – Speaker 1: discontinuation.

17:08 – Speaker 2: People just want relief,

17:10 – Speaker 1: right? Patients come to the clinic

17:11 – Speaker 1: desperate for a cure. They want the

17:13 – Speaker 1: migraines gone, but these medications do

17:16 – Speaker 1: not alter the underlying neurological

17:18 – Speaker 1: predisposition to the disease. They just

17:20 – Speaker 1: turn down the volume.

17:21 – Speaker 2: So, it’s not a cure.

17:22 – Speaker 1: No. If you stop taking the medication,

17:25 – Speaker 1: your headaches will almost certainly

17:26 – Speaker 1: return to their baseline frequency. It

17:28 – Speaker 1: is a chronic management tool.

17:29 – Speaker 2: So, if roughly half of the patients out

17:31 – Speaker 2: there don’t even meet that 50%

17:33 – Speaker 2: improvement threshold after waiting

17:35 – Speaker 2: three months, what happens to them?

17:37 – Speaker 1: That’s the big question. And more than

17:38 – Speaker 1: that, I was shocked by a specific

17:40 – Speaker 1: exclusion criteria mentioned in the

17:42 – Speaker 1: text. Patients with constant unremitting

17:45 – Speaker 1: daily headache, they are systematically

17:47 – Speaker 1: excluded from these drug trials. Where

17:49 – Speaker 1: do they go?

17:50 – Speaker 2: It is one of the most glaring paradoxes

17:53 – Speaker 2: in headache medicine. The patients with

17:55 – Speaker 2: the absolute highest burden, the ones

17:58 – Speaker 2: who never get a pain-free day, are

18:00 – Speaker 2: excluded from the research.

18:01 – Speaker 1: Why?

18:02 – Speaker 2: Because the trials are designed to count

18:03 – Speaker 2: the increase in migraine-free days. If

18:06 – Speaker 2: your baseline is constant uninterrupted

18:08 – Speaker 2: pain, you mathematically don’t fit the

18:10 – Speaker 2: study design.

18:11 – Speaker 1: Oh man, that’s awful.

18:12 – Speaker 2: It is. For those patients and for the

18:14 – Speaker 2: 50% who fail the standard medications,

18:16 – Speaker 2: the systemic chemical approach has

18:18 – Speaker 2: reached its limit. This is where the

18:20 – Speaker 2: medical field looks to the surgical

18:22 – Speaker 2: frontier, specifically peripheral nerve

18:24 – Speaker 2: decompression surgery.

18:25 – Speaker 1: Okay, this sounds like a massive left

18:27 – Speaker 1: turn. Everything we’ve discussed so far,

18:29 – Speaker 1: re-uptake inhibitors, beta receptors,

18:31 – Speaker 1: systemic nervous system tone is

18:33 – Speaker 1: chemical. surgery sounds entirely

18:35 – Speaker 1: different.

18:35 – Speaker 2: It is a fundamentally different

18:37 – Speaker 2: philosophy of pain management. Instead

18:39 – Speaker 2: of chemically altering the brain to

18:41 – Speaker 2: ignore incoming pain signals, this

18:44 – Speaker 2: approach searches for a localized

18:46 – Speaker 2: structural physical source of the pain.

18:49 – Speaker 1: Structural.

18:50 – Speaker 2: Yes. The anatomical concept is that the

18:52 – Speaker 2: peripheral nerves, the nerves that run

18:54 – Speaker 2: outside the skull, supplying sensation

18:56 – Speaker 2: to your scalp, forehead, temples, and

18:58 – Speaker 2: the back of your neck, they can actually

18:59 – Speaker 2: become physically trapped or compressed.

19:02 – Speaker 1: Really?

19:03 – Speaker 2: Yeah. They get crushed by narrow

19:04 – Speaker 2: openings in the fowl, tight bands of

19:07 – Speaker 2: muscle, or even crossing blood vessels.

19:09 – Speaker 1: Oh, I see. So, for years, giving these

19:11 – Speaker 1: patients braintering chemicals was

19:14 – Speaker 1: basically like trying to fix a software

19:16 – Speaker 1: glitch with endless code patches when

19:18 – Speaker 1: the whole time they had a frayed wire

19:20 – Speaker 1: physically pinched in the hardware of

19:22 – Speaker 1: their neck.

19:23 – Speaker 2: The hardware versus software distinction

19:25 – Speaker 2: is a brilliant way to conceptualize it.

19:27 – Speaker 2: When a sensory nerve is chronically

19:29 – Speaker 2: compressed at one of these anatomical

19:30 – Speaker 2: choke points, it becomes inflamed and

19:32 – Speaker 2: fires a continuous distress signal. Your

19:35 – Speaker 2: central nervous system receives that

19:36 – Speaker 2: constant barrage of signaling and

19:39 – Speaker 2: interprets it as a chronic headache or a

19:41 – Speaker 2: migraine. In these specific patients,

19:43 – Speaker 2: the migraine isn’t originating deep in

19:45 – Speaker 2: the brain’s chemistry. It’s a peripheral

19:48 – Speaker 2: nerve signal driving the central pain

19:50 – Speaker 2: cascade.

19:51 – Speaker 1: But if someone has chronic migraines,

19:52 – Speaker 1: how do you know if they have a chemical

19:54 – Speaker 1: software problem or a physical hardware

19:55 – Speaker 1: problem? Yeah. I mean, you can’t just

19:57 – Speaker 1: cut into everyone’s neck to go looking

19:59 – Speaker 1: for a pinched nerve.

20:00 – Speaker 2: No. And ethically and medically, you

20:02 – Speaker 2: shouldn’t. The clinical resource

20:04 – Speaker 2: outlines a very specific diagnostic

20:07 – Speaker 2: bridge to differentiate these patients,

20:09 – Speaker 2: which is the diagnostic peripheral nerve

20:11 – Speaker 2: block.

20:11 – Speaker 1: What’s that?

20:12 – Speaker 2: It is elegantly simple. If a physician

20:14 – Speaker 2: suspects a specific nerve, say the

20:17 – Speaker 2: occipital nerve in the back of the head

20:18 – Speaker 2: is being pinched, they inject a small

20:21 – Speaker 2: amount of local anesthetic right at that

20:23 – Speaker 2: anatomical choke point.

20:24 – Speaker 1: Oh, okay. The anesthetic temporarily

20:27 – Speaker 1: blocks the sodium channels in the nerve,

20:29 – Speaker 1: stopping it from firing.

20:30 – Speaker 2: It’s exactly like flipping off a circuit

20:32 – Speaker 2: breaker in your house to see which room

20:33 – Speaker 2: goes dark. If they numb that specific

20:36 – Speaker 2: nerve in the neck and the migraine

20:38 – Speaker 2: temporarily vanishes, you just found the

20:40 – Speaker 2: frayed wire.

20:41 – Speaker 1: Exactly. If the patient’s headache

20:43 – Speaker 1: significantly improves while that

20:45 – Speaker 1: specific area is numb, it clinically

20:47 – Speaker 1: proves that nerve is the pain generator.

20:50 – Speaker 2: Wow. They are then considered a

20:52 – Speaker 2: candidate for decompression surgery

20:54 – Speaker 2: where a surgeon goes in and physically

20:56 – Speaker 2: removes the tissue or muscle that is

20:58 – Speaker 2: crushing the nerve. And the clinical

21:00 – Speaker 2: results for this are remarkable.

21:03 – Speaker 1: What kind of results are we talking

21:04 – Speaker 1: about?

21:04 – Speaker 2: Well, the source cited a landmark sham

21:07 – Speaker 2: control trial, meaning they even

21:09 – Speaker 2: ethically controlled for the powerful

21:11 – Speaker 2: placebo effect of having surgery by

21:12 – Speaker 2: doing a mock surgery on a control group.

21:15 – Speaker 2: And they found an 83.7%

21:17 – Speaker 2: significant improvement rate for

21:19 – Speaker 2: patients who had the actual

21:20 – Speaker 2: decompression surgery.

21:21 – Speaker 1: 83.7%. And to be clear, those are the

21:24 – Speaker 1: outcomes for the patients who had

21:25 – Speaker 1: already failed the beta blockers and the

21:27 – Speaker 1: anti-depressants. They were the ones

21:28 – Speaker 1: left behind by the chemical options.

21:30 – Speaker 2: Yes. It is a highly statistically

21:32 – Speaker 2: significant result for a very difficult

21:34 – Speaker 2: to treat population. It doesn’t mean

21:36 – Speaker 2: surgery replaces medication. The

21:38 – Speaker 2: pharmacological options we discussed

21:40 – Speaker 2: should always be the first line of

21:41 – Speaker 2: defense.

21:41 – Speaker 1: Right. Of course. But it means for a

21:43 – Speaker 1: specific identifiable subset of

21:45 – Speaker 1: patients, there is a structural solution

21:48 – Speaker 1: when the chemical options run out.

21:50 – Speaker 2: So what does this all mean for you, the

21:52 – Speaker 2: listener?

21:53 – Speaker 1: It leaves us with a pretty provocative

21:55 – Speaker 1: thought to maul over. If two of the most

21:57 – Speaker 1: impactful headache treatments of the

21:59 – Speaker 1: 20th century, beta blockers and

22:01 – Speaker 1: anti-depressants, were discovered

22:03 – Speaker 1: entirely by accident while doctors were

22:05 – Speaker 1: trying to treat chest pain and

22:07 – Speaker 1: depression. Well, what other miraculous

22:09 – Speaker 1: secondary uses for common medications

22:11 – Speaker 1: are just hiding in plain sight right

22:13 – Speaker 1: now?

22:13 – Speaker 2: Such a great question.

22:14 – Speaker 1: What else is out there sitting on a

22:16 – Speaker 1: pharmacy shelf just waiting for an

22:18 – Speaker 1: observant doctor and a communicative

22:19 – Speaker 1: patient to connect the dots? It really

22:21 – Speaker 1: makes you wonder how much of modern

22:23 – Speaker 1: medicine is just waiting for his next

22:24 – Speaker 1: happy accident. This discussion is

22:26 – Speaker 1: intended as an educational resource and

22:28 – Speaker 1: that medical decisions should always be

22:30 – Speaker 1: individualized based on current

22:32 – Speaker 1: evidence-based guidelines and directed

22:34 – Speaker 1: by a physician.